TRANSITION: An Observational Study of the Effects on Sweat Chloride and Clinical Outcomes of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)
Latest Information Update: 29 Jan 2024
At a glance
- Drugs Ivacaftor/tezacaftor (Primary) ; Ivacaftor/lumacaftor
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Acronyms TRANSITION
- 09 Apr 2020 Status changed from recruiting to completed.
- 06 Apr 2020 Planned End Date changed from 1 Mar 2021 to 1 Nov 2020.
- 08 May 2019 Planned End Date changed from 31 Dec 2019 to 1 Mar 2021.